Sold as Inversine. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Mecamylamine Hydrochloride (sold as Inversine), first approved Mar 1, 1956, with 0 new uses approved and 0 published complete response letters.
| Attentional Mechanisms in SCDSubjective Cognitive Decline · Vanderbilt University Medical Center | Early phase 1 | Recruiting | Aug 21, 2023 |
| Treatment of Orthostatic IntoleranceTachycardia, Chronic Orthostatic Intolerance · Satish R. Raj | Phase 1 / Phase 2 | Active, not recruiting | Dec 6, 2005 |
| Mar 1, 1956 | InversineNDA 10251 · New molecular entity | Targacept | 16 | Discontinued |
| Mar 19, 2013 | Mecamylamine HydrochlorideANDA 204054 | Lgm Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
